Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...

Apixaban appeared to serve as a feasible management option for patients with cancer and venous thromboembolism, according to the results of a subgroup analysis from the AMPLIFY trial.However ...

Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine , 2011; 110827230022006 DOI: 10.1056/NEJMoa1107039 Cite This Page : ...

The European Committee for Medicinal Products for Human Use (CHMP) has recommended approval for apixaban (Eliquis, Pfizer and BristolMyers Squibb) for atrial fibrillation (AF). The drug is already ...

Apixaban tied to less stroke and bleeding in patients with/without dementia vs. dabigatran, rivaroxaban or warfarin. Image: Adobe Stock “The prescribing decisions for oral anticoagulants need to ...

Apixaban has also been evaluated for stroke prevention in AF in two Phase III trials, one of which was recently completed. Both include patients with one or more additional stroke risk factors ( ...

Gastrointestinal (GI) bleeds are about 20%–28% less likely in patients with atrial fibrillation (AF) taking apixaban (Eliquis) compared with other direct oral anticoagulants (DOACs), an ...

Apixaban was also more clinically effective than dabigatran etexilate and enoxaparin. Both apixaban and rivaroxaban dominated dabigatran etexilate and enoxaparin in the analyses for total knee ...

The ICER for apixaban compared with enoxaparin/warfarin remained under £3,000 per QALY gained and apixaban dominated rivaroxaban and enoxaparin/dabigatran etexilate in all analyses. In the lifelong ...